Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

J. K. Overbeek; R. ter Heine; H. M.W. Verheul; E. Chatelut; M. A. Rudek; H. Gurney; R. Plummer; D. C. Gilbert; T. Buclin; D. M. Burger; H. J. Bloemendal; N. P. van Erp

ArticleOPEN ACCESS

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

ESMO Open

DOI: 10.1016/j.esmoop.2022.100749

11Citations

9Readers

Cite

CITATION STYLE

APA

Overbeek, J. K., Heine, R. ter, Verheul, H. M. W., Chatelut, E., Rudek, M. A., Gurney, H., … van Erp, N. P. (2023, February 1). Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs. ESMO Open. Elsevier B.V. https://doi.org/10.1016/j.esmoop.2022.100749

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

Cite

Register to see more suggestions